Results 21 to 30 of about 5,478,695 (241)

CAR‐NK cell in cancer immunotherapy; A promising frontier [PDF]

Cancer Science, 2021
AbstractChimeric antigen receptors (CARs) have a unique facet of synthetic biology and offer a paradigm shift in personalized medicine as they can use and redirect the patient's immune cells to attack cancer cells. CAR‐natural killer (NK) cells combine the targeted specificity of antigens with the subsequent intracellular signaling ability of the ...
Faroogh Marofi, Omar F. Abdul‐Rasheed, Heshu Sulaiman Rahman, Hendrik Setia Budi, Abduladheem Turki Jalil, Alexei Valerievich Yumashev, Ali Hassanzadeh, Mahboubeh Yazdanifar, Roza Motavalli, Max Stanley Chartrand, Majid Ahmadi, Angel Cid‐Arreguid, Mostafa Jarahian   +12 more
openaire   +2 more sources

CAR NK Cells: The Future Is Now

Annual Review of Cancer Biology, 2023
Chimeric antigen receptor (CAR) T cell therapy has been a great success in CD19+ hematological diseases. Natural killer (NK) CAR cells offer an alternative to CAR T cells with an intrinsic potential for universal off-the-shelf cell therapeutics.
Martin J. Raftery, Alexander Sebastian Franzén, Gabriele Pecher   +2 more
openaire   +1 more source

CAR-NK Cells: From Natural Basis to Design for Kill [PDF]

Frontiers in Immunology, 2021
Chimeric antigen receptors (CARs) are fusion proteins with an extracellular antigen recognition domain and numerous intracellular signaling domains that have been genetically modified. CAR-engineered T lymphocyte-based therapies have shown great success against blood cancers; however, potential fatal toxicity, such as in cytokine release syndrome, and ...
Muhammad Babar Khawar, Muhammad Babar Khawar, Muhammad Babar Khawar, Muhammad Babar Khawar, Haibo Sun, Haibo Sun   +5 more
openaire   +3 more sources

DataSheet_1_ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.pdf

, 2023
IntroductionMetastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies.
Michael Merker, Elise Gradhand, Marian Groot Koerkamp, Frank C. P. Holstege (16486624), Herman Kreyenberg (16848660), Michael T. Meister, Eva Rettinger (3430253), Frank C. P. Holstege, Herman Kreyenberg, Michael Merker (5470025), Torsten Tonn (308943), Laura M. Moser, Winfried S. Wels (358423), Marian Groot Koerkamp (16848669), Catrin Heim, Catrin Heim (9534383), Peter Bader, Jan-Henning Klusmann (12177185), Eva Rettinger, Halvard B. Bonig (16848663), Evelyn Ullrich (5280524), Peter Bader (111174), Elise Gradhand (14901357), Jarno Drost, Jan-Henning Klusmann, Laura M. Moser (9534386), Evelyn Ullrich, Halvard B. Bonig, Torsten Tonn, Michael T. Meister (16848666), Jarno Drost (9261587), Winfried S. Wels   +31 more
core   +1 more source

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy [PDF]

, 2023
Cancer immunotherapies utilize the capabilities of the immune system to efficiently target malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed promising results against B cell lymphomas.
Schmiedel, Dominik, Fricke, Stephan, Köhl, Ulrike, Ruppel, Katharina Eva   +3 more
core   +4 more sources

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

, 2023
Natural killer (NK) cells are cytotoxic lymphocytes that are critical for the innate immune system. Engineering NK cells with chimeric antigen receptors (CARs) allows CAR-NK cells to target tumor antigens more effectively.
John Sienkiewicz, Hua Zhou, Lijun Wu, Yanwei Huang, Shiming Zhang, Jinying Sun, Hizkia Harto, Shirley Xu, Vita Golubovskaya, Robert Berahovich   +9 more
core   +1 more source

Next-generation cell therapies: the emerging role of CAR-NK cells [PDF]

Hematology, 2020
Abstract T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell malignancies. Despite this progress, there are limitations to CAR-T cell therapy in both the autologous and allogeneic settings ...
Rafet, Basar, May, Daher, Katayoun, Rezvani   +2 more
openaire   +4 more sources

CAR NK Cell Therapy for T Follicular Helper Cells [PDF]

Cell Reports Medicine, 2020
T follicular helper (TFH) cells are associated with the development of both autoimmune disease and T cell malignancies. In this issue, Reighard et al.,1 describe the design of PD-L1 chimeric antigen receptor (CAR) NK cells that effectively target and eliminate TFH cells.
openaire   +4 more sources

IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study [PDF]

, 2011
In an ongoing clinical phase I/II study, 16 pediatric patients suffering from high risk leukemia/tumors received highly purified donor natural killer (NK) cell immunotherapy (NK-DLI) at day (+3) +40 and +100 post haploidentical stem cell transplantation.
Claudia Brehm, Bader Peter, Soerensen, Jan, Klingebiel Thomas, Seidl, Christian, Christian Seidl, Petra S. A. Becker, Bremm Melanie, Koehl Ulrike, Becker, Petra S. A., Jakob R. Passweg, Sabine Huenecke, Andrea Quaiser, Peter Bader, Koehl, Ulrike, Thomas Klingebiel, Ulrike Koehl, Jakob R Passweg, Brehm Claudia, Jan Soerensen, Hermann Kreyenberg, Schwabe Dirk, Becker Petra S. A., Brehm, Claudia, Quaiser, Andrea, Petra S A Becker, Bader, Peter, Sörensen, Jan, Mühl Heiko, Stephan Kloess, Huenecke, Sabine, Mühl, Heiko, Klingebiel, Thomas, Esser Ruth, Klöß, Stephan, Esser, Ruth, Hünecke, Sabine, Kloess, Stephan, Huenecke Sabine, Kreyenberg Hermann, Seidl Christian, Melanie Bremm, Kreyenberg, Hermann, Bremm, Melanie, Heiko Mühl, Ruth Esser, Dirk Schwabe, Soerensen Jan, Köhl, Ulrike, Quaiser Andrea, Passweg, Jakob R., Schwabe, Dirk, Kloess Stephan, Passweg Jakob R.   +53 more
core   +1 more source

The clinical landscape of CAR NK cells [PDF]

Experimental Hematology & Oncology
Abstract Chimeric antigen receptor (CAR) NK cell therapy has emerged as a promising alternative to CAR T cell therapy, offering significant advantages in terms of safety and versatility. Here we explore the current clinical landscape of CAR NK cells, and their application in hematologic malignancies and solid cancers, as well as their
Jørgensen, Lasse Vedel, Birch Christensen, Emil, Barnkob, Mike Bogetofte, Barington, Torben   +3 more
openaire   +3 more sources